Glioblastoma Multiforme of Brain: Clinical Trials

10 trials for Glioblastoma Multiforme of Brain, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 active not recruiting, 1 recruiting, 1 unknown. 10 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 6, Active not recruiting 2, Recruiting 1, Unknown 1
Phase 13Active not recruiting 1, Completed 1, Unknown 1
Phase 31Active not recruiting 1

Follow Glioblastoma Multiforme of Brain: new trials by email Literature Review of Glioblastoma Multiforme of Brain trials Research Report on Glioblastoma Multiforme of Brain

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Ruxolitinib, Temozolomide, Radiation Therapy - Glioblastoma, Brain Cancer
Phase 2RecruitingBaptist Health South Florida1902025-12-032026-10-02
Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma
Cisplatin Plus Temozolomide, Temozolomide - Glioblastoma Multiforme of Brain
Phase 1 / Phase 2UnknownZhongnan Hospital602024-01-012024-01-02
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
TVI-Brain-1, Standard of Care, Radiotherapy - Glioblastoma Multiforme of Brain
Phase 2 / Phase 3Active not recruitingTVAX Biomedical1202023-12-272026-09-29
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab - Glioblastoma Multiforme, Glioblastoma, Adult
Phase 1 / Phase 2CompletedUniversity Hospital, Geneva182018-10-252025-05-13
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
avelumab - Glioblastoma Multiforme of Brain
Phase 2CompletedClinique Neuro-Outaouais382017-05-192025-05-25
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients
Dendritic cell vaccine plus temozolomide chemotherapy - Glioblastoma Multiforme of Brain
Phase 1 / Phase 2Active not recruitingUniversity Hospital, Antwerp202015-12-012026-06-04
Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study
Deep Transcranial Magnetic Stimulation (dTMS) - Glioblastoma Multiforme of Brain
Phase 2CompletedUniversity of Roma La Sapienza152014-11-012015-06-18
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Standard Radiation Therapy, Standard Temozolomide, Belinostat - Glioblastoma Multiforme of Brain
Phase 2CompletedEmory University292014-05-072026-10-30
Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study
Ketogenic Diet, Standardized Diet - Glioblastoma Multiforme of Brain
Phase 2CompletedMid-Atlantic Epilepsy and Sleep Center, LLC422014-02-012022-08-11
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
Antineoplaston therapy (Atengenal + Astugenal) - Glioblastoma Multiforme of Brain
Phase 2CompletedBurzynski Research Institute401995-03-142018-03-22

Narrower conditions

Glioblastoma (4)  ·  Brain Neoplasms (1)

Broader conditions

Astrocytoma (4)  ·  Glioma (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Germ Cell and Embryonal (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Neoplasms, Nerve Tissue (4)  ·  Neoplasms, Neuroepithelial (4)  ·  Neuroectodermal Tumors (4)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Central Nervous System Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Nervous System Diseases (1)  ·  Nervous System Neoplasms (1)

Interventions

Temozolomide (4)  ·  Radiotherapy (2)  ·  Cisplatin (1)  ·  Diet, Ketogenic (1)  ·  Drug Therapy (1)  ·  Standard of Care (1)  ·  antineoplaston A10 (1)  ·  antineoplaston AS 2-1 (1)  ·  avelumab (1)  ·  belinostat (1)  ·  pembrolizumab (1)  ·  ruxolitinib (1)

Sponsors

Baptist Health South Florida (1)  ·  Burzynski Research Institute (1)  ·  Clinique Neuro-Outaouais (1)  ·  Emory University (1)  ·  Mid-Atlantic Epilepsy and Sleep Center, LLC (1)  ·  TVAX Biomedical (1)  ·  University Hospital, Antwerp (1)  ·  University Hospital, Geneva (1)  ·  University of Roma La Sapienza (1)  ·  Zhongnan Hospital (1)

Countries

United States (5)  ·  Belgium (1)  ·  Canada (1)  ·  Switzerland (1)

Top investigators

Gary Wood, PhD (1)  ·  Hui-Kuo Shu, MD, PhD (1)  ·  Manmeet Ahluwalia, M.D., MBA (1)  ·  Marika Rasschaert, MD, PhD (1)  ·  Maurizio Inghilleri, Professor (1)  ·  Nicolas Mach, Prof. (1)  ·  Pavel Klein, M.D. (1)  ·  Stanislaw R. Burzynski, MD, PhD (1)  ·  Zwi N Berneman, MD, PhD (1)

Results publications

PMID 12436090, PMID 12743250, PMID 12893641, PMID 15717053, PMID 15792886, PMID 18798293, PMID 19664713, PMID 19682584, PMID 19833552, PMID 21924290, PMID 22037136, PMID 22629405, PMID 23388348, PMID 25117977, PMID 33292598, PMID 34604752, PMID 404164

NIH funding

F30CA206291 (1), P30CA138292 (1), R21NS100244 (1), U01CA172027 (1)